
US FDA Approves Regeneron Therapy
The US Food and Drug Administration has approved Regeneron Pharmaceuticals drug for adults with generalized myasthenia gravis. The treatment is intended for patients who test positive for specific antibodies.
Insights:

Regeneron Pharmaceuticals won approval from the United States Food and Drug Administration to treat adults with generalized myasthenia gravis on Thursday evening. The treatment targets patients who test positive for anti-acetylcholine receptor antibodies. The regulatory clearance expands the drug's label into a new neuromuscular indication.










